2025-03-20T16:47:07-05:00 2024-12-31 911056739 VINE DAHLEN PLLC 3500 188TH STREET SW STE 322 LYNNWOOD WA 98037 990 2024-01-01 912054035 RIVKIN CENTER FOR OVARIAN CANCER RIVK 2064900847 1200 12TH AVE S STE 1110 SEATTLE WA 98144 MOLLY O'CONNOR CEO 2064900847 2025-03-20 1 0 LORI L SCOTT CPA P01452038 4257716055 2025-03-20 2024 2025-03-06 01:10:19Z MOLLY O'CONNOR 1200 12TH AVE S STE 1110 SEATTLE WA 98144 1790856 0 X WWW.RIVKIN.ORG X 1996 WA END OVARIAN CANCER WITHIN OUR LIFETIMES. 11 11 8 50 0 0 1421107 1523596 5250 157825 3780 7357 -145905 11240 1284232 1700018 120000 290470 0 0 776490 521961 8275 101975 725615 499244 763897 1404009 1678303 -119777 21715 1949824 1970548 31061 30329 1918763 1940219 X WE ENVISION A WORLD WHERE WOMEN LIVE LONGER AND HEALTHIER LIVES BECAUSE OVARIAN CANCER CAN BE PREVENTED, CAUGHT EARLY, OR CURED. 0 1 290470 290470 THE RIVKIN CENTER'S PROGRAMMATIC WORK UNDERWENT DYNAMIC CHANGE IN 2024, AND EVEN BIGGER CHANGES ARE COMING FOR 2025.FOR THREE DECADES, THE RIVKIN CENTER'S SCIENTIFIC GRANT PROGRAM HAS USED A SEED-FUNDING APPROACH THAT LAUNCHES PROMISING NEW RESEARCH AND RESEARCHERS THROUGHOUT THE WORLD. AFTER PAUSING NEW GRANTS IN 2023, THE RIVKIN CENTER FUNDED TWO $75K PILOT STUDY AWARDS IN 2024. THE RIVKIN CENTER AND WASHINGTON STATE'S ANDY HILL CANCER RESEARCH ENDOWMENT (CARE) FUND ALSO CREATED A PUBLIC-PRIVATE PARTNERSHIP TO JOINTLY SUPPORT $1M IN OVARIAN CANCER RESEARCH IN WASHINGTON STATE. IN 2024, THE FIRST TWO GRANTS TOTALING $400K WERE AWARDED; $600K IN GRANTS WILL BE AWARDED IN 2025. BY THE END OF 2024, THE RIVKIN CENTER HAD RAISED ITS $500K IN PRIVATE MATCHING FUNDS. OVARIAN CANCER IS UNDERFUNDED BY FEDERAL FUNDING AGENCIES WHEN COMPARED TO OTHER CANCERS, DESPITE IT STILL HAVING NO UNIVERSAL SCREENING TOOL AND BEING THE DEADLIEST GYNECOLOGICAL CANCER. FOR EVERY DOLLAR INVESTED BY THE RIVKIN CENTER, OUR AWARDEES, ON AVERAGE, LEVERAGE ANOTHER $17.30 FROM OTHER FUNDING SOURCES TO FURTHER THEIR OVARIAN CANCER RESEARCH. 360801 157825 IN SEPTEMBER 2024, THE RIVKIN CENTER HOSTED THE 15TH BIENNIAL OVARIAN CANCER RESEARCH SYMPOSIUM, BRINGING TOGETHER NEARLY 250 RESEARCHERS AND CLINICIANS FROM 11 COUNTRIES WHO CAME TO LEARN ABOUT THE LATEST IN OVARIAN CANCER RESEARCH. THE EVENT HOSTED A SESSION WITH PATIENT ADVOCATES; SCIENTIFIC SESSIONS COVERED THE BIOLOGY OF OVARIAN CANCER, PREVENTION, EARLY DETECTION, & INTERCEPTION, EMERGING THERAPEUTICS, NOVEL IMMUNOTHERAPIES, AND HEALTHCARE DISPARITIES. ON APRIL 30, 2024, THE RIVKIN CENTER ENDED ITS EDUCATION PROGRAM FOCUSED ON OVARIAN AND BREAST CANCER EDUCATION AND RETURNED TO A SOLE FOCUS ON OVARIAN CANCER - BOTH RESEARCH GRANTS AND BETTER SUPPORT FOR THOSE DIAGNOSED WITH OVARIAN CANCER IN THE PACIFIC NORTHWEST. FROM JANUARY TO MARCH 2024 THE EDUCATION TEAM SUPPORTED 15 COLLEGE-CAMPUS WORKSHOPS AND EIGHT PUGET SOUND COMMUNITY WORKSHOPS. COMMUNITY WORKSHOPS WERE HELD IN COORDINATION WITH MERCY HOUSING, MARY'S PLACE, FAMILYWORKS, WASHINGTON RHINESTONE CLUB, SEATTLE JEWISH FESTIVAL AND HERZL NER TAMID AND REACHED PRIMARILY PARTICIPANTS WHO BELONG TO HISTORICALLY UNDER-RESOURCED/UNDERREPRESENTED GROUPS. 651271 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 14 0 1 8 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 11 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 WA X X THE ORGANIZATION 2064900847 1200 12TH AVE S STE 1110 SEATTLE WA 98144 MOLLY O'CONNOR CEO 40.00 X 161600 0 24082 PAULINE MIDDLEHURST DEVELOPMENT DIRECTOR (UNTIL 4/2024) 40.00 X 29586 0 5475 MELISSA RIVKIN PRESIDENT 1.00 X X 0 0 0 AMY SING VICE PRESIDENT 1.00 X X 0 0 0 ALEX SMITH SECRETARY 1.00 X X 0 0 0 THOMAS BROWN MEMBER 1.00 X 0 0 0 EVA CORETS MEMBER 1.00 X 0 0 0 AUDREY COVNER MEMBER 1.00 X 0 0 0 KRISTIN HAWES MEMBER 1.00 X 0 0 0 BOB MAHLER MEMBER 1.00 X 0 0 0 FERNANDA MUSA MEMBER 1.00 X 0 0 0 KATERIE SCHEI MEMBER 1.00 X 0 0 0 KATIE VAN KESSEL MEMBER 1.00 X 0 0 0 ANDREA REWITZ MIZER MEMBER (UNTIL 6/2024) 1.00 X 0 0 0 191186 0 29557 1 0 1 0 0 470371 103500 949725 25678 1523596 SYMPOSIUM 900999 157825 157825 157825 7444 7444 9891 9978 -87 -87 -87 92100 470371 80860 11240 11240 1700018 157825 0 18597 290470 290470 220743 18568 68495 133680 237691 133340 104351 28803 145 28658 34724 16134 8305 10285 11273 3600 7673 58235 58235 101975 101975 18467 14129 4338 253709 253709 41643 9 5396 36238 38464 5847 4822 27795 30263 15314 6277 8672 638 548 90 8852 8852 SYMPOSIUM EXPENSES 151727 151727 SUMMERUN EXPENSES 125047 125047 RELATIONSHIP BUILDING 23172 1440 45 21687 MISC EXPENSE 2407 218 2189 1678303 651271 301417 725615 1792874 1770189 50000 18385 4609 138565 145750 1949824 1970548 31061 30329 31061 30329 X 1791875 1549825 126888 390394 1918763 1940219 1949824 1970548 21715 -259 0 X 0 0 0 X 1617870 1807977 1717789 1421107 1523596 8088339 1617870 1807977 1717789 1421107 1523596 8088339 258636 7829703 663 3896 7444 12003 11240 11240 8111582 0.96520 0.97360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X X X X 1 KIM ISAAC BROOKS CONSULTING 4315 NORTHEAST 42ND STREET SEATTLE WA 98105 DEVELOPMENT CONSULTING 0 500000 94500 405500 500000 94500 405500 WA GALA 562471 470371 92100 215 3000 44478 17703 15464 562471 470371 92100 215 3000 44478 17703 15464 80860 11240 1 FRED HUTCHINSON CANCER CENTER PO BOX 19024 SEATTLE WA 981091024 911935159 501(C)3 100000 0 OVARIAN CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)3 75000 0 OVARIAN CANCER RESEARCH UNIVERSITY OF COLORADO DENVER 1800 GRANT STREET SUITE 200 DENVER CO 80203 846000555 501(C)3 75000 0 OVARIAN CANCER RESEARCH UNIVERSITY OF WASHINGTON 1410 NE CAMPUS PARKWAY SEATTLE WA 98195 916001537 GOVERNMENT 100000 0 OVARIAN CANCER RESEARCH 4 PART I, LINE 2: EACH AWARDEE AND AWARDEE'S INSTITUTIONAL OFFICIAL SIGN A "TERMS OF AWARD" AGREEMENT WITH THE RIVKIN CENTER OUTLINING THE USE AND MONITORING OF AWARDED FUNDS. WITH EACH FUNDED PROJECT, THERE IS A BUDGET APPROVED BY RIVKIN CENTER SCIENTIFIC LEADERSHIP. NO CHANGES EXCEEDING 20% (INCREASE OR DECREASE) ON ANY BUDGETARY LINE ITEM MAY BE MADE TO AN APPROVED BUDGET WITHOUT PRIOR WRITTEN APPROVAL FROM THE RIVKIN CENTER. AT THE END OF THE AWARD PERIOD, A FULL REPORT IS MADE TO THE RIVKIN CENTER BY THE GRANTEES AND CONTRACTS OFFICE OF THE AWARDEE'S INSTITUTION TO SHOW ALL THE EXPENDITURES MADE RELATING TO THE FUNDED PROJECT. IF THERE ARE FUNDS REMAINING, THE INSTITUTION IS REQUIRED TO RETURN THE UNSPENT FUNDS TO THE RIVKIN CENTER WITHIN 60 DAYS OF THE AWARD'S END. 0 0 0 0 0 0 0 0 0 MOLLY O'CONNOR CEO 161600 0 0 0 0 0 0 0 24082 0 185682 0 0 0 X 1 9978 FMV X T-SHIRTS 1 15000 FMV X AUCTION ITEMS 1 700 FMV 0 0 0 FORM 990, PART III, LINE 3 ON APRIL 1, 2025, THE RIVKIN CENTER WILL COMBINE WITH THE OVARIAN CANCER RESEARCH ALLIANCE (OCRA), ENSURING THAT OUR MISSION TO END OVARIAN CANCER IN OUR LIFETIMES WILL CONTINUE TO GROW AND BE REALIZED. THEY ALSO HAVE HAD A THREE-DECADE COMMITMENT TO FUNDING OVARIAN CANCER RESEARCH. OCRA'S ABILITY TO SECURE FUNDING THROUGH GOVERNMENT GRANTS AND PARTNERSHIPS WITH BIOTECH COMPANIES MAKES THEM A POWERFUL PARTNER IN AMPLIFYING OUR SHARED MISSION. PARTNERSHIP WITH OCRA WILL ENSURE SUSTAINABLE, LONG-TERM INVESTMENTS IN THE OVARIAN CANCER RESEARCH THAT HAS ALWAYS BEEN THE PURPOSE OF OUR WORK. THIS PARTNERSHIP REPRESENTS A UNITING OF STRENGTHS: OCRA HAS RECOGNIZED THE RIVKIN CENTER'S UNIQUE EXPERTISE IN IDENTIFYING AND FUNDING EARLY-STAGE, INNOVATIVE RESEARCH THAT OFTEN LEADS TO MUCH LARGER FEDERAL GRANTS. IN TURN, WE ARE HONORED TO PARTNER WITH AN ORGANIZATION THAT HAS ALREADY INVESTED $128M TOWARD OUR SHARED GOAL OF ENDING OVARIAN CANCER. OCRA ALSO HAS TRUSTED INFORMATION AND RESOURCES TO SUPPORT THE OVARIAN CANCER COMMUNITY - PATIENTS, SURVIVORS, FAMILIES, ADVOCATES, AND MEDICAL PROFESSIONALS. AS PART OF THIS TRANSITION: - THE RIVKIN CENTER WILL RETIRE AS A SEPARATE ENTITY ON APRIL 1, 2025 2025 SCIENTIFIC GRANTS WILL BE ANNOUNCED IN MARCH 2025 AS PLANNED - OCRA WILL CONTINUE TO AWARD THE RIVKIN PILOT GRANTS WITH AROUND $400K A YEAR DEDICATED TO SUPPORTING NEW IDEAS IN OVARIAN CANCER RESEARCH THROUGHOUT THE WORLD - THE SUMMERUN WILL CONTINUE! THE 2025 SUMMERUN WILL BE HELD JULY 13 AT SEWARD PARK - THE BIENNIAL OVARIAN CANCER RESEARCH SYMPOSIUM WILL CONTINUE AND BE RENAMED FOR DR. RIVKIN - OUR SCIENTIFIC PROGRAMS DIRECTOR, DR. JACKIE LANG, WILL JOIN OCRA, ENSURING CONTINUITY AND DRIVING THE PROGRAMS CENTRAL TO OUR SHARED MISSION AND MELISSA RIVKIN WILL JOIN THE OCRA BOARD OF DIRECTORS FORM 990, PART VI, SECTION B, LINE 11B THE BOARD REVIEWS THE FORM 990 PRIOR TO THE SUBMISSION TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C ALL BOARD MEMBERS REVIEW AND SIGN THE CONFLICT OF INTEREST DOCUMENT ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST.